Dialysis dose and gender: A different hypothesis  by Lowrie, Edmund G. et al.
Letters to the Editor 1291
5. MARTIN P, HEISKARI N, ZHOU J, et al: High mutation detection rate
in the COL4A5 collagen gene in suspected Alport syndrome using
PCR and direct DNA sequencing. J Am Soc Nephrol 9:2291–2301,
1998
Reply from the Author
I thank Professors Kashtan and Rizzoni and Dr. Mas-
sella for their comments. They rightly point out the value
of immunostaining of renal biopsies for the diagnosis of
X-linked and autosomal Alport syndrome and the utility
of skin immunofluorescence in diagnosis of many cases
of X-linked Alport syndrome. The use of confocal laser
scanning microscopy (CLSM) [1–3] is an elegant tech-
nique to improve the spatial resolution of a5(IV) chain
distribution in basement membranes.
Ueda et al [3], also using CLSM, have reported that
compared with a2(IV), a5(IV) expression in GBM is re-
duced in patients with TBMD. The reduction in a5(IV)
but not a3(IV) and a4(IV) is difficult to reconcile with
the genetic evidence implicating mutations of COL4A3
and COL4A4 in TBMD.
Confirmation and clarification of the results of CLSM
of EBM and GBM is eagerly awaited. Until sequenc-
ing of the relevant collagen genes or other comprehen-
sive genetic testing is routinely and readily available, im-
munofluorescence of skin biopsies is a minimally invasive
means for diagnosis of many cases of X-linked Alport syn-
drome. If quantitative comparisons of the different a(IV)
chains in GBM permit a positive diagnosis of TBMD, this
will further strengthen our diagnostic hand.
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Dialysis dose and gender: A
different hypothesis
To the Editor: A recent report [1] suggested that fe-
males who are smaller than males need higher dialysis
0 10 20 30 40 50 60
V, L 
20
30
40
50
60
70
Kt
, L
/R
x
Fig. 1. Illustration of three relationships discriminating the high (upper
symbols) and low (lower symbols) Kt/V groups for males (solid circles)
and females (open squares) in the HEMO study. The relationships are
1) Kt = 1.16 V (thin black line) representing the low dose HEMO
study Kt/V for both genders, 2) Kt = 30 + 0.5 V (thick black line), and
3) 35 + 0.3 V (thick gray line).
dose (Kt/V) than males. The idea that smaller persons re-
quire higher Kt per L of V is not new [2], and suggests that
a 0-intercept rule for judging Kt per unit of V is incorrect
[3].
Figure 1 illustrates a non-0 intercept rule (thick black
line: Kt = 30 + 0.5 V) [3]. The mean Kt ± SD (Table 3) [1]
is shown for females (squares) and males (circles) at the
mean V (Table 2) [1] for the high (upper symbols) and
low (lower symbols) hemodialysis (HEMO) treatment
groups. The steep, thin black line is a 0-intercept Kt/V
rule (Kt = 0 + 1.16 V) [1]. All groups were treated at or
above the Kt for their V by that rule. Females in the low
treatment group (Kt = 38.2; eKt/V = 1.17), however, had
marginally worse (P = 0.02) survival than females in the
high treatment group [1].
The gray line (Kt = 35 + 0.3 V) is a rotation of the ear-
lier black line [3], and better discriminates among groups
according to outcome. Only low Kt/V females received
substantially suboptimal therapy according to this illus-
trative rule.
The point of this exercise was not to recommend a new
rule for judging treatment. It only shows that one need not
resort to speculations about different uremic toxin gen-
eration in males and females [1] to explain this marginal
survival difference. All one needs to do is accept the pos-
sibility that a 0-intercept Kt/V rule may be suboptimal.
EDMUND G. LOWRIE, NORMA OFSTHUN, and ZHENGSHENG LI
Lexington, Massachusetts
Correspondence to Edmund G. Lowrie, 21 Edmonds Road, Concord,
MA 01742.
E-mail: edlowrie@prodigy.net
REFERENCES
1. DEPNER T, DAUGIRDAS J, GREENE T, et al: Dialysis dose and the effect
of gender and body size on outcome in the HEMO study. Kidney Int
65:1386–1394, 2004
1292 Letters to the Editor
2. LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM: Body size, dialysis dose
and death risk relationships among hemodialysis patients. Kidney Int
62:1891–1897, 2002
3. LOWRIE EG: Letter to the editor. Kidney Int 63:1962, 2003
Reply from the Authors
We appreciate the attempts by Lowrie and others to
explain the suspected gender effect as simply reflecting
the difference in body size. In the analysis of our find-
ings we explored functions of body size that might dimin-
ish or erase the difference between the genders in their
response to the dialysis dose, expressed either as Kt or
Kt/V. As detailed in our paper [1], the dependence of the
dose effect on gender was not explained by differences
in body size expressed as several different parameters,
including weight, height, body surface area, water vol-
ume, and body mass index (Table 6). The dose effect was
not significantly associated with any of these size parame-
ters. In fact, the nonsignificant weak trends that were de-
tected were further diminished by correction for gender
(Table 5). Furthermore, the suggested increased mortal-
ity of males treated at the higher dose could not be ex-
plained by any consideration of body size.
A non-0 intercept for a linear relationship between
body size and required solute clearance is a clear math-
ematic concept that is difficult to understand physio-
logically. It implies an enormous amount of dialysis (or
kidney function) for very small people, and a near infinite
amount for even smaller biological organisms. Probably
the relationship is nonlinear but with a 0 intercept (e.g., a
power function of body mass). This is consistent with the
universal scaling law that relates physiologic functions to
the 3/4 power of body mass and to the current practice
of correcting the creatinine clearance or GFR for body
surface area (2/3 power of body mass) [2, 3, 4].
The effect of body size as an independent mortality risk
factor in hemodialyzed patients reported by Lowrie et al
[5] is now commonly accepted, and was also observed in
the HEMO Study (Table 4). However, the marked rota-
tion of the line depicting dose versus size in the graph
provided by Lowrie et al suggests that the relationship of
size with outcome can be altered by changing the dose.
Post-hoc analyses of our data [1] do not support such a
dependence of the effect of dose on the risk associated
with body size in a range of eKt/V from 1.16 to 1.53, but
do indicate that women were more responsive to the dose
effect than men. The risk associated with female gender,
in contrast to small body size, can be viewed as favorable
because females appeared to respond to the higher dose,
whereas both small patients and males did not.
Finally, we must reiterate two important limitations
that we noted in our paper. First, the finding of a dif-
ferent dose effect in men and women must be viewed as
a suggestion only because the level of significance was
not high in the context of multiple subgroup analyses.
Second, because the power of the study to detect effects
in subgroups is limited, it cannot rule out the possibility
of an undetected dependence of the dose effect on body
size.
TOM DEPNER, JOHN DAUGIRDAS, and TOM GREENE,
FOR THE HEMO STUDY GROUP
Sacramento, California
Correspondence to Tom Depner, University of California, Davis,
UCD Professional Building, Sacramento, CA.
E-mail: tadepner@ucdavis.edu
REFERENCES
1. DEPNER T, DAUGIRDAS J, GREENE T, et al: Dialysis dose and the effect
of gender and body size on outcome in the HEMO study. Kidney Int
65:1386–1394, 2004
2. RENKIN EM, GILMORE JP: Glomerular filtration, in Handbook of
Physiology-Renal Physiology, edited by Orloff J, Berliner RW, Wash-
ington, DC, American Physiology Society, 1973, pp 185–248
3. WEST GB, BROWN JH, Enquist BJ: A general model for the origin of
allometric scaling laws in biology. Science 276:122–126, 1997
4. SINGER MA, MORTON AR: Mouse to elephant: Biological scaling and
Kt/V. Am J Kidney Dis 35:306–309, 2000
5. LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM: Body size, dialysis dose
and death risk relationships among hemodialysis patients. Kidney Int
62:1891–1897, 2002
Prevention of acute
renal failure with
N-acetylcysteine—Enough
is enough?
To the Editor: As clinicians in daily practice we would
like to comment on the enormous amount of publica-
tions published in the last three years on the preven-
tion of radiocontrast-induced nephropathy (RCIN) by
N-acetylcysteine (NAC). Just recently, the last of four
meta-analyses was completed [1–4].
The dilemma a clinician faces is the enormous amount
of data in this field, and deciding if the information is
clinically valid or not. Traditionally, meta-analyses have
been the key tool in estimating a treatment benefit of
contradictory randomized controlled trial (RCT) results.
However, even at this evidence level results are inconclu-
sive. How is the clinician going to solve this problem?
From a practical point of view, it seems to be more
sensible to use the drug. A physician who is trying to
prevent RCIN in his patient is likely to administer a drug
if there is any evidence for a beneficial effect, especially
given the low adverse event profile for many years and
low cost of the drug.
